VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LSTA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LSTALisata Therapeutics, Inc.
$1.04$9M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLSTABalance Sheet

Lisata Therapeutics, Inc. (LSTA) Balance Sheet

30Y historyFree accessUpdated daily

Total assets have eroded significantly from $54.7 million in 2023Q4 to $14.1 million in 2026Q1, reflecting the company's reliance on liquidating its cash reserves to fund operations.

Income StatementBalance SheetCash FlowRatios

LSTA Balance Sheet

Annual statement

LSTA Balance Sheet

Lisata Therapeutics, Inc. (LSTA) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Mar'97Mar'96Mar'95
Total Current Assets287.75M17.7M34.58M53.92M71.88M96.18M35.33M25.97M44.11M61.11M24.65M29.27M36.28M50.83M16.71M38.61M46.88M31.8M530.42K2.38M528.16K507.32K49.1K228.97K1.06M1.57M3.09M4.44M14.17K135.07K7.3M
Cash & Short-Term Investments282.72M15.96M31.25M50.53M69.23M94.97M34.57M25.16M43.05M55.08M14.71M20.32M26.25M46.13M13.74M3.94M15.61M7.16M430.79K2.3M436.66K488.87K27.87K210.95K19.25K1.55M2.85M4.37M13.17K66100K
Cash Only282.72M15.96M16.21M22.59M32.15M24.65M16.51M14.03M10.3M29.16M14.71M20.32M19.17M46.13M13.74M3.94M15.61M7.16M430.79K2.3M436.66K488.87K27.87K210.95K19.25K51.27K473.01K1.64M13.17K66100K
Short-Term Investments0015.04M27.94M37.07M70.32M18.06M11.13M32.75M25.92M007.08M000512000000001.5M2.38M2.73M000
Accounts Receivable200K700K900K000000234.46K138.77K2.57M3.11M1.86M1.05M1.01M5.87M5.73M7.19K24.61K9.05K0001M000179125K125K
Days Sales Outstanding1K1.5K328.5-------1.4441.6563.346.326.8436.730.69180.6931.4338.7772.24---4.49K-----2.17
Inventory0000000005M3.58M2.91M2.57M1.27M1.11M647.75K21.02M12.98M0000000000000
Days Inventory Outstanding---------4.91K2.9K52.7259.7635.813427.34154.5624.4-------------
Other Current Assets4.83M1.05M2.43M3.39M2.65M00004.77M15.53M2.91M2.57M0032.37M3.38M4.71M00000000236.05K71.62K003.6M
Total Non-Current Assets360.66M41K424K770K1.16M826K671K1.18M474K2.27M27.18M27.93M89.99M38.99M37.7M116.72M96.14M74.24M1.29M1.4M666.81K135.36K50.34K82.72K123.83K261.91K1.53M726.25K7471.14K2.5M
Property, Plant & Equipment177K18K72K175K296K62K57K100K165K256.9K17.15M17.06M15.96M12.84M11.15M11.62M37M21.3M99.49K164.12K96.14K1.49K3.45K1.94K074.16K525.87K655K747135.07K1.4M
Fixed Asset Turnover1.78x9.44x13.89x-------2.06x1.32x1.12x1.14x1.28x0.87x1.89x0.54x0.84x1.41x0.48x23.70x14.09x33.40x-1.45x1.01x0.02x--15.04x
Goodwill64.73M0000000007.01M7.01M25.21M11.12M11.12M11.12M27M29.86M558.17K558.17K558.17K0000000001.3M
Intangible Assets292.9M0192K263K334K000002.31M2.88M47.56M13.88M14.48M15.09M29.27M22.84M633.79K669K00000015.56K16.78K00-100K
Long-Term Investments0000000000000000000000000000000
Other Non-Current Assets2.85M23K160K332K528K764K614K1.08M309K1.43M713.45K976.77K1.26M1.15M947.31K78.9M2.87M238.94K2.44K8.78K12.5K133.87K46.9K80.78K123.83K187.75K991.26K54.47K0-133.93K-100K
Total Assets648.41M17.74M35M54.69M73.03M97.01M36M27.15M44.58M63.38M51.83M57.21M126.28M89.82M54.41M155.33M143.02M106.03M1.82M3.78M1.19M642.68K99.44K311.69K1.18M1.84M4.62M5.17M14.91K136.2K9.8M
Asset Turnover0.00x0.01x0.03x-------0.68x0.39x0.14x0.16x0.26x0.06x0.49x0.11x0.05x0.06x0.04x0.05x0.49x0.21x0.07x0.06x0.12x0.00x--2.15x
Asset Growth %2723%-49.31%-36%-25.11%-24.71%169.45%32.59%-39.09%-29.66%22.27%-9.39%-54.7%40.59%65.08%-64.97%8.6%34.88%5712.3%-51.68%215.92%85.94%546.27%-68.09%-73.66%-35.57%-60.24%-10.69%34569.87%-89.05%-98.61%27.27%
Total Current Liabilities20.42M3.07M5.61M6.59M6.38M4.52M3.51M5.98M5.62M9.31M19.5M21.02M16.24M9.81M9.95M36.45M32.84M25.49M961.14K444.23K838.3K1.75M1.29M1.02M1.14M489.5K463.65K872.87K666.62K455.31K9.1M
Accounts Payable6.57M1.02M1.28M2.42M2.65M1.93M1.02M1.49M762K1.34M2.23M4.11M5.66M3.35M2.56M2.29M14.29M8.26M508.8K158.45K372.35K256.98K149.17K87.9K344.28K130.62K144.82K561.87K51.21K4.93K183.12K
Days Payables Outstanding90.6K2.55K----5.91K8.37K1.24K1.32K1.8K74.37131.894.5878.0596.55104.99397.565.81K2.33K6.07K3.79K1.61K735.692.07K674.58475.49-2.74K--4.3
Short-Term Debt875K00000000159K3.69M5.36M1.93M594.21K3.64M3.78M12.6M11.99M028.74K222.14K349.67K569.12K409.51K147.59K21.05K23.46K22.66K082.63K82.63K
Deferred Revenue (Current)00000000005.1M5.35M4.33M1.82M1.47M1.12M1.71M2.27M9.85K2.9K2.42K617.2K88.88K92.11K157.81K000000
Other Current Liabilities12.97M10000003.1M4.68M8.76M3.43M1.52M1.72M687.61K28.16M232.07K806.99K177.77K0210.38K720.81K524.39K433.2K491.51K337.83K295.37K288.33K377.1K317.37K8.64M
Current Ratio14.09x5.76x6.16x8.18x11.26x21.27x10.08x4.35x7.85x6.56x1.26x1.39x2.23x5.18x1.68x1.06x1.43x1.25x0.55x5.35x0.63x0.29x0.04x0.22x0.93x3.22x6.65x5.09x0.02x0.30x0.80x
Quick Ratio14.09x5.76x6.16x8.18x11.26x21.27x10.08x4.35x7.85x6.02x1.08x1.25x2.08x5.05x1.57x1.04x0.79x0.74x0.55x5.35x0.63x0.29x0.04x0.22x0.93x3.22x6.65x5.09x0.02x0.30x0.80x
Cash Conversion Cycle-89.6K---------1.1K20-8.73-12.47-17.22-32.580.2407.54-------------
Total Non-Current Liabilities36.35M72K72K210K327K485K254K624K1.51M3.87M28.27M12.91M51.96M17.98M11.64M38.75M23.69M20.95M533.37K14.73K64.57K707.92K743.18K791.74K865.89K973.06K1.02M375.39K404.93K265.75K3.6M
Long-Term Debt00000000002.68M11.41M14.72M3.55M171.53K0000024.44K0681.17K09.51K32.11K53.13K76.59K000
Capital Lease Obligations1.23M000305K485K254K624K0000000000014.73K40.13K0000000000
Deferred Tax Liabilities29.44M0000000001.07M932.66K18.18M4.38M3.6M3.77M5.96M00000000000000
Other Non-Current Liabilities5.69M72K72K210K22K0001.51M3.87M19.92M562K19.06M10.05M7.76M34.8M17.45M20.95M533.37K00681.17K0791.74K856.37K940.95K970.09K298.8K404.93K00
Total Liabilities56.77M3.14M5.68M6.8M6.71M5.01M3.76M6.6M7.13M13.19M47.77M33.92M68.2M27.79M21.59M75.2M56.54M46.45M961.14K458.95K902.87K2.46M2.03M1.81M2.01M1.46M1.49M1.25M666.62K455.31K12.7M
Total Debt00137K168K485K714K624K978K0159.18K6.79M16.78M16.64M4.15M3.81M3.78M12.6M11.99M14.73K68.87K286.71K349.67K569.12K409.51K157.11K53.16K76.59K99.25K400K82.63K6.4M
Net Debt-282.72M-15.96M-16.07M-22.43M-31.67M-23.93M-15.89M-13.05M-10.3M-29M-7.91M-3.54M-2.53M-41.98M-9.92M-152.04K-3.01M4.83M-416.06K-2.24M-149.95K-139.21K541.25K198.57K137.85K1.89K-396.42K-1.54M386.83K82.56K6.3M
Debt / Equity0.00x-0.00x0.00x0.01x0.01x0.02x0.05x-0.00x1.67x0.72x0.29x0.07x0.12x0.05x0.15x0.20x0.02x0.02x0.98x----0.14x0.02x0.03x---
Debt / EBITDA-0.00x------------------------------
Net Debt / EBITDA12.84x------------------------------
Interest Coverage---------3397.40x-73.04x-15.87x-45.17x-72.54x-136.54x-22.00x-12.05x-38.19x-283.64x-791.49x-475.18x-3.40x-11.10x--3.75x---248.32x----7.26x
Total Equity7.64M14.6M29.32M47.89M66.32M92M32.24M20.55M37.45M50.19M4.07M23.28M58.07M62.03M32.82M80.13M86.49M59.59M863.18K3.32M292.11K-1.82M-1.93M-1.5M-823.89K373.73K3.13M3.92M-651.71K-319.11K-2.9M
Equity Growth %-224.58%-50.2%-38.79%-27.79%-27.91%185.34%56.87%-45.12%-25.38%1134.23%-82.54%-59.91%-6.37%88.99%-59.04%-7.35%45.15%6803.22%-73.97%1035.27%116.07%5.91%-28.55%-82.4%-320.45%-88.06%-20.17%701.86%-104.23%89%-480%
Book Value per Share0.821.683.525.9312.8024.9531.3329.8657.9883.949.3272.00265.94453.95355.661356.682512.646865.64213.821514.94210.91-5477.48-8904.47-8587.28-5529.502525.2221155.9447257.90-40731.81-19944.06-12033.20
Total Shareholders' Equity7.64M14.86M29.57M48.15M66.58M92.25M32.5M20.82M37.73M50.51M4.88M23.71M58.51M62.54M33.18M62.03M48.66M24.8M863.18K3.32M292.11K-1.82M-1.93M-1.5M-823.89K373.73K3.13M3.92M-651.71K-319.11K-2.9M
Common Stock11K9K8K8K8K4K19K11K10K9.48K8.21K56.73K36.78K27.2K163.75K109.33K63.81K37.19K7.71K4.83K20.78K70.55K41.03K26.33K22.4K22.29K22.28K12.51K263.04K263.04K1.2M
Retained Earnings-578.86M-564.65M-548.07M-528.08M-507.24M-453.02M-425.55M-417.4M-397.98M-381.81M-404.79M-372.13M-291.25M-236.37M-197.39M-143.09M-95.32M-70.88M-39.99M-30.75M-20.31M-14.26M-12.51M-10.76M-9.69M-8.49M-6.41M-4.33M-2.45M-2.12M-3.8M
Treasury Stock-708K-708K-708K-708K-708K-708K-708K-708K-708K-708K-707.64K-707.64K-705.74K-705.74K-665.6K00000000000000-204.71K-204.71K
Accumulated OCI9K-37K-81K-42K-29K-70K-13K2K-32K-27.98K04861.33K-3.02M04.15M2.78M-67.92K-21.9K-738.8K-371.67K-602.01K-602.01K-602.01K-602.01K-700.5K-239.74K-85.31K00-1M
Minority Interest0-254K-254K-254K-254K-254K-254K-263K-272K-318.28K-817.43K-429.71K-441.05K-516.04K-356.97K18.11M37.83M34.79M0000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent capital funding shortfall

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Erosion Reflects Burn

As reported in recent financial filings, Lisata's total assets have declined from $54.7 million in 2023Q4 to $14.1 million in 2026Q1, a contraction that underscores the company's reliance on liquidating its balance sheet to fund ongoing clinical development and operational overhead.

The consistent downward trend in total assets suggests that the company is consuming its capital base at a rate that outpaces any potential value creation from its R&D pipeline. Investors should monitor this trajectory, as the depletion of assets without a corresponding commercial milestone may necessitate further dilutive financing to maintain operations.

Narrowing Runway Amidst Cash Depletion

Based on the company's 2026Q1 balance sheet, cash reserves have dwindled to $13.1 million, down from $22.6 million in 2023Q4, indicating a tightening liquidity buffer that leaves the firm with limited flexibility to navigate unexpected clinical trial delays or rising research costs.

While the current ratio of 4.23 appears superficially healthy, it is largely a function of the company's lack of significant short-term liabilities rather than robust cash generation. This liquidity profile warrants caution, as the current cash position may be insufficient to support the company's long-term clinical roadmap without external capital intervention.

Accumulated Deficit Weighs on Equity

According to historical balance sheet data, Lisata's retained earnings have plummeted to a deficit of $569.1 million as of 2026Q1, reflecting the persistent and significant capital destruction inherent in the company's long-term pursuit of its proprietary oncology platform.

The erosion of equity highlights the substantial cost of the company's strategic pivots and the ongoing reliance on equity financing to cover operating losses. This trend suggests that shareholders are bearing the full weight of the firm's clinical-stage risk, with little evidence of value accumulation on the balance sheet.

Hidden Risks in Asset Composition

Analysis of the balance sheet reveals that the company's asset base is almost entirely composed of cash, with negligible PPE of $16,000, suggesting that the firm lacks tangible collateral and is entirely dependent on the intangible value of its intellectual property to justify its valuation.

The absence of meaningful physical assets implies that the company's balance sheet provides no downside protection in the event of clinical failure. Investors should be aware that the valuation is tethered exclusively to the success of the CendR platform, making the balance sheet highly sensitive to binary regulatory outcomes.

LSTA — Frequently Asked Questions

Quick answers to the most common questions about buying LSTA stock.

What are the total assets of Lisata Therapeutics, Inc. (LSTA)?

As of 2025, Lisata Therapeutics, Inc. (LSTA) had total assets of $17.7M including $17.7M in current assets.

How much debt does Lisata Therapeutics, Inc. (LSTA) have?

Lisata Therapeutics, Inc. (LSTA) carries total debt of $0.0M, offset by $16.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Lisata Therapeutics, Inc.?

Lisata Therapeutics, Inc. (LSTA) has total shareholders' equity (book value) of $14.9M ($1.68 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Lisata Therapeutics, Inc.'s current ratio and liquidity?

Lisata Therapeutics, Inc. (LSTA) reported a current ratio of 5.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.